Free Trial
NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

Cingulate logo
$5.50 +0.13 (+2.42%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$5.60 +0.09 (+1.73%)
As of 07/25/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cingulate Stock (NASDAQ:CING)

Key Stats

Today's Range
$5.29
$5.60
50-Day Range
$3.33
$5.73
52-Week Range
$1.80
$20.83
Volume
56,614 shs
Average Volume
102,045 shs
Market Capitalization
$28.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00
Consensus Rating
Buy

Company Overview

Cingulate Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

CING MarketRank™: 

Cingulate scored higher than 62% of companies evaluated by MarketBeat, and ranked 377th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cingulate has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cingulate has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cingulate's stock forecast and price target.
  • Earnings Growth

    Earnings for Cingulate are expected to grow in the coming year, from ($11.69) to ($4.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cingulate is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cingulate is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cingulate has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cingulate's valuation and earnings.
  • Percentage of Shares Shorted

    4.75% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cingulate has recently decreased by 18.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cingulate does not currently pay a dividend.

  • Dividend Growth

    Cingulate does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.75% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cingulate has recently decreased by 18.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cingulate has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cingulate this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cingulate insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.27% of the stock of Cingulate is held by insiders.

  • Percentage Held by Institutions

    41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cingulate's insider trading history.
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the country are buzzing in anticipation
See More Headlines

CING Stock Analysis - Frequently Asked Questions

Cingulate's stock was trading at $4.93 at the beginning of the year. Since then, CING shares have increased by 11.6% and is now trading at $5.50.

Cingulate Inc. (NASDAQ:CING) released its earnings results on Thursday, May, 8th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by $0.04.

Cingulate's stock reverse split before market open on Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cingulate (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
5/08/2025
Today
7/26/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CING
CIK
1862150
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$61.00
Low Price Target
$11.00
Potential Upside/Downside
+372.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.55 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-229.78%
Return on Assets
-142.28%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
1.87
Quick Ratio
1.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.32 per share
Price / Book
2.37

Miscellaneous

Outstanding Shares
5,150,000
Free Float
4,875,000
Market Cap
$28.33 million
Optionable
Not Optionable
Beta
-0.79

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CING) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners